Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries in Hong Kong and Taiwan. The company's pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury that is in phase 1, 2, and 3 clinical trials, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded in 1994 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does Eusol Biotech Co.,Ltd. (6652) operate in?
Eusol Biotech Co.,Ltd. belongs to the Other sector and operates in the industry.
What is Eusol Biotech Co.,Ltd. (6652) current stock price?
As of the latest data, Eusol Biotech Co.,Ltd. stock price is NT$1.95, with a previous close of NT$1.95.
What is Eusol Biotech Co.,Ltd. (6652) current market capitalization?
Eusol Biotech Co.,Ltd. market cap is approximately 267.15 million.
What is Eusol Biotech Co.,Ltd. (6652) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.30.
Does Eusol Biotech Co.,Ltd. (6652) pay dividends?
No. Eusol Biotech Co.,Ltd. does not pay a dividend.
What is Eusol Biotech Co.,Ltd. (6652) beta (volatility) score?
Eusol Biotech Co.,Ltd. has a beta of -0.075, indicating lower volatility than the overall market.
